Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 14/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 13/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 13/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 13/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL516715 | 0.82 | CYP2D6 (0.58) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL516755 | 0.81 | SLC6A3 (0.41) | — | |
| SCHEMBL516110 | 0.81 | OPRM1 (0.43) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL516554 | 0.80 | L3MBTL1 (0.49) | OPRM1OPRK1CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL516154 | 0.79 | OPRM1 (0.39) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL632624 | 0.74 | OPRL1 (0.59) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL2677605 | 0.74 | OPRL1 (0.59) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL515916 | 0.74 | CYP1A2 (0.42) | OPRL1OPRM1OPRD1OPRK1CYP3A4 | |
| SCHEMBL515716 | 0.74 | OPRL1 (0.40) | OPRL1OPRM1OPRD1OPRK1CYP3A4 | |
| SCHEMBL515991 | 0.73 | CYP3A4 (0.41) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414323-B1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | PF MEDICAMENT (FR) | 2013-03-13 | — | — | EP | disclosed |
| EP-2414323-A1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | Pierre Fabre Médicament (FR) | 2012-02-08 | — | — | EP | disclosed |
| US-20120029013-A1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | PIERRE FABRE MEDICAMENT (FR) | 2012-02-02 | — | — | US | disclosed |
| WO-2010112597-A1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | PIERRE FABRE MEDICAMENT (FR) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029013-A1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | CYP11B2, BCAT1, CYP11B1 | OPRL1 453/4885OPRM1 338/4885OPRD1 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.